Q-omics provides the consensus-scored AK6 profile across patient tissues and cancer cell-line models. AK6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, AK6 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, AK6 RNA expression shows 17,989 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LIHC, and UVM as cancer lineages where AK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AK6 survival associations across molecular data types. AK6 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AK6 RNA expression–survival associations across cancer types. High AK6 expression shows unfavorable associations in KICH, HNSC, ESCA, KIRP, UVM and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for AK6 RNA expression.
This table summarizes AK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AK6 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, KIRC and CHOL. The LIHC box plot shows higher AK6 RNA expression in tumor versus normal tissue (log2 FC = +1.177, t-test p < 0.001).
This table shows molecular features associated with AK6 in patient tissues and cancer cell lines. In patient samples, AK6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
